Literature DB >> 22085493

Bortezomib enhances radiation-induced apoptosis in solid tumors by inhibiting CIP2A.

Chao-Yuan Huang1, Chia-Cheng Wei, Kuei-Chiu Chen, Hui-Ju Chen, Ann-Lii Cheng, Kuen-Feng Chen.   

Abstract

Previously, we demonstrated that cancerous inhibitor of protein phosphatase 2A (CIP2A) mediates bortezomib-induced apoptosis in hepatocellular carcinoma cells. Herein, we report that bortezomib sensitizes solid tumor cells to radiation-induced apoptosis. Treatment with a combination of bortezomib and radiation downregulated CIP2A in a dose-dependent manner in solid tumor cells. Knockdown of CIP2A enhanced radiation-induced apoptosis in cancer cells, and ectopic expression of CIP2A in cancer cells abolished radiation-induced apoptosis. Finally, our in vivo data showed that bortezomib and radiation combination treatment decreased tumor growth significantly. Thus, bortezomib sensitized solid tumor cells to radiation through the inhibition of CIP2A.
Copyright © 2011 Elsevier Ireland Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 22085493     DOI: 10.1016/j.canlet.2011.11.005

Source DB:  PubMed          Journal:  Cancer Lett        ISSN: 0304-3835            Impact factor:   8.679


  14 in total

1.  Helical tomotherapy and systemic targeted therapies in solitary plasmacytoma: Pilot study.

Authors:  Nadia Wiazzane; Cyrus Chargari; Corine Plancher; Jerome Tamburini; Bernard Asselain; Alain Fourquet; Didier Bouscary; Youlia M Kirova
Journal:  World J Radiol       Date:  2013-06-28

Review 2.  Treatment of Liver Cancer.

Authors:  Chun-Yu Liu; Kuen-Feng Chen; Pei-Jer Chen
Journal:  Cold Spring Harb Perspect Med       Date:  2015-07-17       Impact factor: 6.915

3.  Radiosensitization of Cancer Cells by Inactivation of Cullin-RING E3 Ubiquitin Ligases.

Authors:  Dongping Wei; Meredith A Morgan; Yi Sun
Journal:  Transl Oncol       Date:  2012-10-01       Impact factor: 4.243

Review 4.  Therapeutic targeting of PP2A.

Authors:  Caitlin M O'Connor; Abbey Perl; Daniel Leonard; Jaya Sangodkar; Goutham Narla
Journal:  Int J Biochem Cell Biol       Date:  2017-10-26       Impact factor: 5.085

5.  CIP2A regulates MYC translation (via its 5'UTR) in colorectal cancer.

Authors:  S Denk; S Schmidt; Y Schurr; G Schwarz; F Schote; M Diefenbacher; C Armendariz; F Dejure; M Eilers; Armin Wiegering
Journal:  Int J Colorectal Dis       Date:  2020-10-19       Impact factor: 2.571

6.  CIP2A is a target of bortezomib in human triple negative breast cancer cells.

Authors:  Ling-Ming Tseng; Chun-Yu Liu; Kung-Chi Chang; Pei-Yi Chu; Chung-Wai Shiau; Kuen-Feng Chen
Journal:  Breast Cancer Res       Date:  2012-04-26       Impact factor: 6.466

7.  Afatinib induces apoptosis in NSCLC without EGFR mutation through Elk-1-mediated suppression of CIP2A.

Authors:  Ting-Ting Chao; Cheng-Yi Wang; Yen-Lin Chen; Chih-Cheng Lai; Fang-Yu Chang; Yi-Ting Tsai; Chung-Hao H Chao; Chung-Wai Shiau; Yuh-Chin T Huang; Chong-Jen Yu; Kuen-Feng Chen
Journal:  Oncotarget       Date:  2015-02-10

8.  Tamoxifen induces apoptosis through cancerous inhibitor of protein phosphatase 2A-dependent phospho-Akt inactivation in estrogen receptor-negative human breast cancer cells.

Authors:  Chun-Yu Liu; Man-Hsin Hung; Duen-Shian Wang; Pei-Yi Chu; Jung-Chen Su; Tsung-Han Teng; Chun-Teng Huang; Ting-Ting Chao; Cheng-Yi Wang; Chung-Wai Shiau; Ling-Ming Tseng; Kuen-Feng Chen
Journal:  Breast Cancer Res       Date:  2014-09-17       Impact factor: 6.466

9.  CIP2A influences survival in colon cancer and is critical for maintaining Myc expression.

Authors:  Armin Wiegering; Christina Pfann; Friedrich Wilhelm Uthe; Christoph Otto; Lukas Rycak; Uwe Mäder; Martin Gasser; Anna-Maria Waaga-Gasser; Martin Eilers; Christoph-Thomas Germer
Journal:  PLoS One       Date:  2013-10-01       Impact factor: 3.240

Review 10.  PP2A-Mediated Anticancer Therapy.

Authors:  Weibo Chen; Zhongxia Wang; Chunping Jiang; Yitao Ding
Journal:  Gastroenterol Res Pract       Date:  2013-11-07       Impact factor: 2.260

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.